Drug Origin Transparency Act of 2026
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Drug Origin Transparency Act of 2026, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Trade, Environment.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H4F72D7FE9AE0494FAF90F2E982DB0F7A: 1. Short title This Act may be cited as the Drug Origin Transparency Act of 2026.
- Section H646C9317B86A4EE1964D106AF908B160: 2. Enhanced drug manufacturing amount information reporting Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended— in...
- Section HE9AB3703E6A045B49241E68DA7E0BF09: 3. Require drug labeling to include original manufacturer and supply chain information Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352)...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Drug Origin Transparency Act of 2026, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Trade, Environment
Primary Purpose
This bill, Drug Origin Transparency Act of 2026, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeReferred to the House Committee on Energy and Commerce.
Introduced in House
Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology